Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?

Coccaro, Nicoletta; Anelli, Luisa; Zagaria, Antonella; Perrone, Tommasina; Specchia, Giorgina; Albano, Francesco

doi:10.3390/cancers12010185

Cited by 23 publications

(24 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the introduction of rituximab in combination with conventional chemotherapy, significant improvement of treatment outcomes has been observed [ 4 , 5 ]. Nevertheless, treatment strategies are often highly individualized in elderly patients, who are more likely to suffer from life-threatening chemotherapy-related toxicity due to chronic or weakness-associated diseases [ 6 ]. As a result, nationwide database analyses in many countries showed that more than 50% of the elderly patients did not receive anthracycline-containing regimens as the first-line treatment [ 7 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study

et al. 2021

View full text Add to dashboard Cite

Nutritional assessments, including the Geriatric Nutritional Risk Index (GNRI), have emerged as prediction tools for long-term survival in various cancers. This study aimed to investigate the therapeutic strategy and explore the prognostic factors in the elderly patients (≥ 65 years) with diffuse large B cell lymphoma (DLBCL). The cutoff value of the GNRI score (92.5) was obtained using the receiver operating characteristic curve. Among these patients (n = 205), 129 (62.9%) did not receive standard R–CHOP chemotherapy. Old age (≥80 years), poor performance status, low serum albumin level, and comorbidities were the major factors associated with less intensive anti-lymphoma treatment. Further analysis demonstrated that a lower GNRI score (<92.5) was linked to more unfavorable clinical features. In the patients who received non-anthracycline-containing regimens (non-R–CHOP), multivariate analysis showed that a low GNRI can serve as an independent predictive factor for worse progression-free (HR, 2.85; 95% CI, 1.05–7.72; p = 0.039) and overall survival (HR, 2.98; 95% CI, 1.02–8.90; p = 0.045). In summary, nutritional evaluation plays a role in DLBCL treatment and the GNRI score can serve as a feasible predictive tool for clinical outcomes in frail elderly DLBCL patients treated with non-anthracycline-containing regimens.

show abstract

Section: Introductionmentioning

confidence: 99%

Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…SHUFANG XIE 1,2* , WEIMIN FAN 2,3* , CHEN YANG 2,4 , WEN LEI 5 , HONGYING PAN 6 , XIANGMIN TONG 2,7 , YI WU 8 and SHIBING WANG 2,7 patients suffer from treatment-refractory or relapsed disease with associated high mortality rate (3,4).Chemotherapeutic drugs can cause extensive DNA damage within both tumor and healthy cells (5), such that even patients that survive chemotherapy suffer significant systemic toxicity and renal failure in a dose-dependent manner (6).…”

Section: Beclin1-armed Oncolytic Vaccinia Virus Enhances the Therapeutic Efficacy Of R-chop Against Lymphoma In Vitro And In Vivomentioning

confidence: 99%

“…Diffuse large B cell lymphoma (DLBCL) is the most common form of NHL, accounting for 30–40% of new cases. Rituximab, Cyclophosphamide, Epirubicin, Vindesine, Prednisolone (R-CHOP) is the first-line standard of care treatment for these patients and can achieve a 60% overall survival (OS) rate ( 2 ); however, up to 40% of patients suffer from treatment-refractory or relapsed disease with associated high mortality rate ( 3 , 4 ). Chemotherapeutic drugs can cause extensive DNA damage within both tumor and healthy cells ( 5 ), such that even patients that survive chemotherapy suffer significant systemic toxicity and renal failure in a dose-dependent manner ( 6 ).…”

Section: Introductionmentioning

confidence: 99%

Beclin1‑armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R‑CHOP against lymphoma in vitro and in vivo

et al. 2021

View full text Add to dashboard Cite

Non-Hodgkin lymphoma (NHL) is a form of lymphoid malignancy, with diffuse large B cell lymphoma (DLBCL) being the most common NHL isoform. Approximately half of patients with DLBCL are successfully cured via first-line Rituximab, Cyclophosphamide, Epirubicin, Vindesine, Prednisolone (R-CHOP) treatment. However, 30–40% of patients with DLBCL ultimately suffer from treatment-refractory or relapsed disease. These patients often suffer from high mortality rates owing to a lack of suitable therapeutic options, and all patients are at a high risk of serious treatment-associated dose-dependent toxicity. As such, it is essential to develop novel treatments for NHL that are less toxic and more efficacious. Oncolytic Vaccinia virus (OVV) has shown promise as a means of treating numerous types of cancer. Gene therapy strategies further enhance OVV-based therapy by improving tumor cell recognition and immune evasion. Beclin1 is an autophagy-associated gene that, when upregulated, induces excess autophagy and cell death. The present study aimed to develop an OVV-Beclin1 therapy capable of inducing autophagic tumor cell death. OVV-Beclin1 was able to efficiently kill NHL cells and to increase the sensitivity of these cells to R-CHOP, thereby decreasing the dose-dependent toxic side effects associated with this chemotherapeutic regimen. The combination of OVV-Beclin1 and R-CHOP also significantly improved tumor growth inhibition and survival in a BALB/c murine model system owing to the synergistic induction of autophagic cell death. Together, these findings suggest that OVV-Beclin1 infection can induce significant autophagic cell death in NHL, highlighting this as a novel means of inducing tumor cell death via a mechanism that is distinct from apoptosis and necrosis.

show abstract

“…This is a proteasome inhibitor used to suppress Diffuse large B-cell lymphoma (DLBCL) progression [ 223 , 224 , 225 ]. DLBCL is the most frequent non-Hodgkin lymphoma, showing variable clinical presentations as well as variable therapy responses [ 226 , 227 , 228 ]. In vitro studies on DLBCL CRL-2630 cells showed that BTZ treatment significantly inhibited the proliferation of DLBCL CRL-2630 cells [ 229 ].…”

Section: Hmga Proteins As Targetable Markersmentioning

confidence: 99%

HMGA Proteins in Hematological Malignancies

Minervini

Coccaro

Anelli

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

The high mobility group AT-Hook (HMGA) proteins are a family of nonhistone chromatin remodeling proteins known as “architectural transcriptional factors”. By binding the minor groove of AT-rich DNA sequences, they interact with the transcription apparatus, altering the chromatin modeling and regulating gene expression by either enhancing or suppressing the binding of the more usual transcriptional activators and repressors, although they do not themselves have any transcriptional activity. Their involvement in both benign and malignant neoplasias is well-known and supported by a large volume of studies. In this review, we focus on the role of the HMGA proteins in hematological malignancies, exploring the mechanisms through which they enhance neoplastic transformation and how this knowledge could be exploited to devise tailored therapeutic strategies.

show abstract

Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?

Cited by 23 publications

References 120 publications

Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study

Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study

Beclin1‑armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R‑CHOP against lymphoma in vitro and in vivo

HMGA Proteins in Hematological Malignancies

Contact Info

Product

Resources

About